HFSA Heart Failure Seminars

Focus on Hypertrophic Cardiomyopathy

Price

• Member: FREE
• Non-Member: $59.00

Credits

• 1.5 CME Credits

Full Details

Hypertrophic cardiomyopathy (HCM) is estimated to affect some 700,000 Americans. Treatment usually includes the use of non-vasodilating beta-blockers followed by non-dihydropyridine calcium channel blockers if these therapies are not effective. Since the release of the most recent guidelines, mavacamten has been approved, and clinical trial data on emerging therapies including aficamten, ranolazine, and evolving gene therapies have been published. In our commitment to providing education that enhances clinical skills and improves patient outcomes, HFSA has identified a need for education in the selection and utilization of current and emerging therapies for HCM.

The HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM) is part of the educational seminar series, featuring a multidisciplinary panel of experts presenting a case-based program that is designed to provide the most current information on the genetics, pathophysiology, diagnosis, clinical trial data, and optimal use of current and emerging treatment options for the management of patients with HCM.

The Heart Failure Society of America acknowledges Bristol Myers Squibb and Cytokinetics for providing an independent educational grant to support HFSA Heart Failure Seminar: Focus on Hypertrophic Cardiomyopathy (HCM)

Failure to Sleep

Price

• Member: FREE
• Non-Member: $59.00

Credits

• 1.5 CME Credits
• 1.5 CNE Credits

Full Details

The HFSA Heart Failure: Focus on Sleep, Failure to Sleep, features a multidisciplinary panel of HF experts who are presenting a case-based program that is designed to provide the most current information on the diagnosis and utilization of emerging, novel, and current treatments for the management of sleep-disordered breathing (SDB) in patients with heart failure (HF). Among the topics that will be discussed in this program are the physiology and pathophysiology of SDB in HF, pathways for the screening and diagnosis of SBD, treatment options for CSA and OSA, and the impact of pharmacotherapies for insomnia and SBD for the HF population.

This program is part of the HFSA’s ongoing Focus On seminar series which brings together healthcare providers (HCPs), including researchers, cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure. This case-based program is being developed by practicing clinicians and is designed to provide the most current information on the pathophysiology, diagnosis, and management of HF patients with SDBs.

The Heart Failure Society of America acknowledges Zoll and Inspire for providing an independent educational grant to support Heart Failure Seminar: Focus on Sleep.

Navigating the HF Patient Journey: Devices and New Guidelines

Price

• Member: $29.00
• Non-Member: $59.00

Credits

• 1.5 CME Credits
• 1.5 CNE Credits
• 1.5 CPE Credits

Full Details

The standards, competencies, and clinical data relating to the use of device therapy in heart failure (HF) continue to evolve rapidly. This creates challenges for practicing clinicians trying to stay up-to-date and provide optimum evidence-based care to their patients. Navigating the HF Patient Journey: Devices and New Guidelines will feature a multidisciplinary panel of HF experts presenting a case-based program designed to provide the most current information on the timing selection, and utilization of emerging, novel, and current devices for the management of heart failure. The program will also include information on recently published clinical trials and guidelines on device therapies for HF patients. Among the topics that will be discussed in this program are implantable cardiac defibrillators, cardiac resynchronization therapy (biventricular pacing), monitoring devices, temporary and durable mechanical circulatory support, and devices that reduce heart failure hospitalizations.

Debates on Best Outcomes with Percutaneous vs Surgical Interventions

Price

• Member: $49.00
• Non-Member: $89.00

Credits

• 1.5 CME Credits
• 1.5 CNE Credits

Full Details

This seminar will feature heart failure experts discussing percutaneous and surgical interven-tions. Despite the advances in medical therapy, with growing benefit from the “4 pillars” of guide-line directed medical therapy (GDMT), subsets of patients derive signification improvement in out-comes utilizing advanced percutaneous and surgical interventions via improvement in coronary flow, valvular function, and pump function.

Price

• Member: $0.00
• Non-Member: $50.00

Credits

N/A

Full Details

This virtual seminar will feature a multidisciplinary panelist of heart failure experts discussing the challenges and opportunities with implementing the updated Guideline-Directed Medical Therapy (GDMT). Attendees will be presented with case study vignettes that will drive meaningful and engaging discussions. Conversations amongst the panelist include how to navigate cost and availability of medication, and how the new value statements may help to support and inform patient engagement.

Everything you want to know, and not afraid to ask: The evidence, the how, and the challenges.

Price

• Member: $35.00
• Non-Member: $50.00

Credits

• 1.5 CNE Credits
• 1.5 CPE Credits
• 1.5 CEU Credits

Full Details

The optimization of GDMT in the treatment of HF has been shown to reduce morbidity and mortality and improve patient outcomes. However, many HF patients do not receive GDMT and/or achieve the recommended target dose of their medications. Studies have shown that while most patients are managed by cardiologists or primary care practitioners, GDMT and target doses of medication can also be successfully achieved by expanding this role to other providers. Education on GDMT, optimizing medications, and these successful strategies are needed to expand patient outcomes. This program will provide practitioners with updated information on the universal definition of heart failure, guideline-directed medical therapies (GDMT), and strategies that optimize medical therapies (OMT) to improve patient outcomes.

Original Seminar Date:  April 22,2022
Product Expiration Date: May 6, 2023